Clinical Trials Browser

Active not recruiting × Cholangiocarcinoma × surufatinib × Clear all

NCT06239532 2024-11-21

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma